Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Pharmacokinetics and the drug-target residence time concept.

Dahl G, Akerud T.

Drug Discov Today. 2013 Aug;18(15-16):697-707. doi: 10.1016/j.drudis.2013.02.010. Epub 2013 Mar 14. Review.

PMID:
23500610
2.

The importance of drug-target residence time.

Zhang R, Monsma F.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):488-96. Review.

PMID:
19562645
3.

The drug-target residence time model: a 10-year retrospective.

Copeland RA.

Nat Rev Drug Discov. 2016 Feb;15(2):87-95. doi: 10.1038/nrd.2015.18. Epub 2015 Dec 18. Review.

PMID:
26678621
4.

Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century.

Kenakin T, Bylund DB, Toews ML, Mullane K, Winquist RJ, Williams M.

Biochem Pharmacol. 2014 Jan 1;87(1):64-77. doi: 10.1016/j.bcp.2013.10.024. Epub 2013 Nov 19. Review.

PMID:
24269285
5.

Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs.

Zhang R, Monsma F.

Expert Opin Drug Discov. 2010 Nov;5(11):1023-9. doi: 10.1517/17460441.2010.520700. Epub 2010 Sep 16. Review.

PMID:
22827742
6.

A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels.

Yin N, Pei J, Lai L.

Mol Biosyst. 2013 Jun;9(6):1381-9. doi: 10.1039/c3mb25471b. Epub 2013 Mar 11.

PMID:
23478789
7.

Drug-target residence time and its implications for lead optimization.

Copeland RA, Pompliano DL, Meek TD.

Nat Rev Drug Discov. 2006 Sep;5(9):730-9. Epub 2006 Aug 4. Review. Erratum in: Nat Rev Drug Discov. 2007 Mar;6(3):249.

PMID:
16888652
8.

Drug-therapy networks and the prediction of novel drug targets.

Spiro Z, Kovacs IA, Csermely P.

J Biol. 2008 Jul 31;7(6):20. doi: 10.1186/jbiol81. Review.

9.

Drug-target residence time: critical information for lead optimization.

Lu H, Tonge PJ.

Curr Opin Chem Biol. 2010 Aug;14(4):467-74. doi: 10.1016/j.cbpa.2010.06.176. Epub 2010 Jul 19. Review.

10.

Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.

Clas SD, Sanchez RI, Nofsinger R.

Drug Discov Today. 2014 Jan;19(1):79-87. doi: 10.1016/j.drudis.2013.08.014. Epub 2013 Aug 27. Review.

PMID:
23993918
11.

Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.

Tabata K, Hamakawa N, Sanoh S, Terashita S, Teramura T.

Eur J Drug Metab Pharmacokinet. 2009 Apr-Jun;34(2):117-28.

PMID:
19645221
12.

A network view of disease and compound screening.

Schadt EE, Friend SH, Shaywitz DA.

Nat Rev Drug Discov. 2009 Apr;8(4):286-95. doi: 10.1038/nrd2826.

PMID:
19337271
13.

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Smith DA, Di L, Kerns EH.

Nat Rev Drug Discov. 2010 Dec;9(12):929-39. doi: 10.1038/nrd3287.

PMID:
21119731
14.

Challenges in development of targeted liposomal therapeutics.

Sawant RR, Torchilin VP.

AAPS J. 2012 Jun;14(2):303-15. doi: 10.1208/s12248-012-9330-0. Epub 2012 Mar 14. Review.

15.

Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

Chimalakonda AP, Yadav R, Marathe P.

AAPS J. 2013 Jul;15(3):717-27. doi: 10.1208/s12248-013-9477-3. Epub 2013 Apr 16.

16.

Target engagement in lead generation.

Durham TB, Blanco MJ.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):998-1008. doi: 10.1016/j.bmcl.2014.12.076. Epub 2015 Jan 12. Review.

17.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
18.

Passive transdermal systems whitepaper incorporating current chemistry, manufacturing and controls (CMC) development principles.

Van Buskirk GA, Arsulowicz D, Basu P, Block L, Cai B, Cleary GW, Ghosh T, González MA, Kanios D, Marques M, Noonan PK, Ocheltree T, Schwarz P, Shah V, Spencer TS, Tavares L, Ulman K, Uppoor R, Yeoh T.

AAPS PharmSciTech. 2012 Mar;13(1):218-30. doi: 10.1208/s12249-011-9740-9. Epub 2012 Jan 4. Review.

19.

Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.

Meanwell NA.

Chem Res Toxicol. 2011 Sep 19;24(9):1420-56. doi: 10.1021/tx200211v. Epub 2011 Jul 26. Review.

PMID:
21790149
20.

A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.

Li C, Liu B, Chang J, Groessl T, Zimmerman M, He YQ, Isbell J, Tuntland T.

Drug Discov Today. 2013 Jan;18(1-2):71-8. doi: 10.1016/j.drudis.2012.09.004. Epub 2012 Sep 13. Review.

PMID:
22982770
Items per page

Supplemental Content

Write to the Help Desk